Company intelligence / Profile preview

Shenghe Biopharma

Wuhan, Hubei, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Shenghe Biopharma is currently advancing its lead candidate SSGJ-609, a CD3/CD19 bispecific antibody, through Phase 2 clinical trials for B-cell malignancies. The company's pipeline also features SSGJ-611, an IL-15-based fusion protein in Phase 1 for solid tumors, alongside several other oncology-focused monoclonal antibodies.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibodyRecombinant fusion proteinCytokine
Industry: Biotech

Partnerships

Sanhome Pharmaceutical

Beyond the preview

Go deeper on Shenghe Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenghe Biopharma.

Explore the full profile